BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is rare with limited evidence-based guidelines. This retrospective study evaluates the use of chemotherapy in patients with resected ICC. METHODS: The Surveillance Epidemiology and End Results (SEER) program database was used to identify patients with resected ICC. Patients were stratified by date of diagnosis (2000-2004, 2005-2009, 2010-2014), T, and N stage. Multivariable logistic regression models identified predictors of chemotherapy use. Kaplan-Meier and Cox proportional hazard models were used to identify survival trends. RESULTS: One thousand and two hundred twenty-three patients met inclusion criteria. Chemotherapy utilization increased over time (33% to 41%, P≤0.05). Chemotherapy use increased in lymph node (LN) positive patients [32% to 60% in 2010-2014; (P≤0.05) and T3/T4 disease (40% to 60% in 2010-2014; P≤0.01], but not in patients with LN negative or T1/T2 disease. LN positivity was associated with utilization of chemotherapy in 2005-2009 and 2010-2014. Overall survival increased from 32 to 41 months (P≤0.05). In LN positive patients, chemotherapy was associated with a decreased hazard ratio of death (P≤0.05) and T3/T4 disease was associated with an increased hazard ratio of death (P≤0.05). CONCLUSIONS: Adjuvant chemotherapy use in ICC has increased. More LN positive or patients with T3/T4 tumors are receiving chemotherapy, which may explain the improvement in overall survival. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is rare with limited evidence-based guidelines. This retrospective study evaluates the use of chemotherapy in patients with resected ICC. METHODS: The Surveillance Epidemiology and End Results (SEER) program database was used to identify patients with resected ICC. Patients were stratified by date of diagnosis (2000-2004, 2005-2009, 2010-2014), T, and N stage. Multivariable logistic regression models identified predictors of chemotherapy use. Kaplan-Meier and Cox proportional hazard models were used to identify survival trends. RESULTS: One thousand and two hundred twenty-three patients met inclusion criteria. Chemotherapy utilization increased over time (33% to 41%, P≤0.05). Chemotherapy use increased in lymph node (LN) positive patients [32% to 60% in 2010-2014; (P≤0.05) and T3/T4 disease (40% to 60% in 2010-2014; P≤0.01], but not in patients with LN negative or T1/T2 disease. LN positivity was associated with utilization of chemotherapy in 2005-2009 and 2010-2014. Overall survival increased from 32 to 41 months (P≤0.05). In LN positive patients, chemotherapy was associated with a decreased hazard ratio of death (P≤0.05) and T3/T4 disease was associated with an increased hazard ratio of death (P≤0.05). CONCLUSIONS: Adjuvant chemotherapy use in ICC has increased. More LN positive or patients with T3/T4 tumors are receiving chemotherapy, which may explain the improvement in overall survival. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.
Authors: John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater Journal: Lancet Oncol Date: 2019-03-25 Impact factor: 41.316
Authors: Xu-Feng Zhang; Qinyu Chen; Charles W Kimbrough; Eliza W Beal; Yi Lv; Jeffery Chakedis; Mary Dillhoff; Carl Schmidt; Jordan Cloyd; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-12-20 Impact factor: 3.452
Authors: Malini D Sur; Haejin In; Susan M Sharpe; Marshall S Baker; Ralph R Weichselbaum; Mark S Talamonti; Mitchell C Posner Journal: Ann Surg Oncol Date: 2014-12-05 Impact factor: 5.344
Authors: Scott Kizy; Ariella M Altman; Schelomo Marmor; Keith Wirth; Jane Y Ching Hui; Todd M Tuttle; Jason W Denbo; Eric H Jensen Journal: HPB (Oxford) Date: 2018-09-28 Impact factor: 3.647
Authors: Milind Javle; Tanios Bekaii-Saab; Apurva Jain; Ying Wang; Robin Katie Kelley; Kai Wang; Hyunseon C Kang; Daniel Catenacci; Siraj Ali; Sunil Krishnan; Daniel Ahn; Andrea Grace Bocobo; Mingxin Zuo; Ahmed Kaseb; Vincent Miller; Philip J Stephens; Funda Meric-Bernstam; Rachna Shroff; Jeffrey Ross Journal: Cancer Date: 2016-09-13 Impact factor: 6.860
Authors: Mairead G McNamara; Thomas Walter; Anne M Horgan; Eitan Amir; Sean Cleary; Elizabeth L McKeever; Trisha Min; Elaine Wallace; David Hedley; Monika Krzyzanowska; Malcolm Moore; Steven Gallinger; Paul Greig; Stefano Serra; Laura A Dawson; Jennifer J Knox Journal: Am J Clin Oncol Date: 2015-08 Impact factor: 2.339
Authors: Hari Nathan; Timothy M Pawlik; Christopher L Wolfgang; Michael A Choti; John L Cameron; Richard D Schulick Journal: J Gastrointest Surg Date: 2007-09-05 Impact factor: 3.452
Authors: Zeljka Jutric; W Cory Johnston; Helena M Hoen; Pippa H Newell; Maria A Cassera; Chet W Hammill; Ronald F Wolf; Paul D Hansen Journal: HPB (Oxford) Date: 2016-01 Impact factor: 3.647
Authors: Yao Xiao; Baoluhe Zhang; Jordan M Cloyd; Laura Alaimo; Gang Xu; Shunda Du; Yilei Mao; Timothy M Pawlik Journal: Cancers (Basel) Date: 2022-07-05 Impact factor: 6.575